Active Ingredient History

  • Now
Alpelisib (BYL719) is a PI3Kα-selective inhibitor. PI3K-AKT-mTOR pathway is frequently activated in cancer, therefore investigational PI3K inhibitor alpelisib is considered to be effective as an anticancer agent and has been in clinical development by Novartis. Alpelisib have demonstrated activity in preclinical models of solid tumors and had favorable tolerability profiles, with the most common adverse events consistent with “on-target” inhibition of PI3K in early clinical studies. There are ongoing clinical trials of alpelisib in a range of cancer types, including breast cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, lymphoma, and glioblastoma multiforme. Combination therapy with other chemo therapeutics may be preferable.   NCATS

  • SMILES: CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
  • Mol. Mass: 441.47
  • ALogP: 3.84
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$431.9379 - $8094.0750
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

alpelisib | byl719 | byl-719 | nvp-byl719


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue